414.74M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.

Similar securities

Based on sector and market capitalization

Report issue